BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8363988)

  • 1. Suramin in combination with mitomycin C in hormone-resistant prostate cancer. A phase II clinical study.
    Rapoport BL; Falkson G; Raats JI; de Wet M; Lotz BP; Potgieter HC
    Ann Oncol; 1993 Aug; 4(7):567-73. PubMed ID: 8363988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma.
    Falcone A; Antonuzzo A; Danesi R; Allegrini G; Monica L; Pfanner E; Masi G; Ricci S; Del Tacca M; Conte P
    Cancer; 1999 Aug; 86(3):470-6. PubMed ID: 10430255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UK studies on suramin therapy in hormone resistant prostate cancer.
    Kehinde EO; Terry TR; Mistry N; Horsburgh T; Sandhu DP; Bell PR
    Cancer Surv; 1995; 23():217-29. PubMed ID: 7621460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.
    Eisenberger MA; Sinibaldi VJ; Reyno LM; Sridhara R; Jodrell DI; Zuhowski EG; Tkaczuk KH; Lowitt MH; Hemady RK; Jacobs SC
    J Clin Oncol; 1995 Sep; 13(9):2174-86. PubMed ID: 7666076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suramin/epidoxorubicin association in hormone-refractory prostate cancer: preliminary results of a pilot phase II study.
    Miglietta L; Canobbio L; Granetto C; Vannozzi MO; Esposito M; Boccardo F
    J Cancer Res Clin Oncol; 1997; 123(7):407-10. PubMed ID: 9260594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study.
    Calvo E; Cortés J; Rodríguez J; Sureda M; Beltrán C; Rebollo J; Martínez-Monge R; Berián JM; de Irala J; Brugarolas A
    Cancer; 2001 Nov; 92(9):2435-43. PubMed ID: 11745301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer.
    Safarinejad MR
    Urol Oncol; 2005; 23(2):93-101. PubMed ID: 15869993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
    Kobayashi K; Vokes EE; Vogelzang NJ; Janish L; Soliven B; Ratain MJ
    J Clin Oncol; 1995 Sep; 13(9):2196-207. PubMed ID: 7666078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suramin, an active drug for prostate cancer: interim observations in a phase I trial.
    Eisenberger MA; Reyno LM; Jodrell DI; Sinibaldi VJ; Tkaczuk KH; Sridhara R; Zuhowski EG; Lowitt MH; Jacobs SC; Egorin MJ
    J Natl Cancer Inst; 1993 Apr; 85(8):611-21. PubMed ID: 8468719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
    Comella P; Biglietto M; Casaretti R; De Lucia L; Avallone A; Maiorino L; Di Lullo L; De Cataldis G; Rivellini F; Comella G
    Oncology; 2001; 60(2):127-33. PubMed ID: 11244327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.
    Bowden CJ; Figg WD; Dawson NA; Sartor O; Bitton RJ; Weinberger MS; Headlee D; Reed E; Myers CE; Cooper MR
    Cancer Chemother Pharmacol; 1996; 39(1-2):1-8. PubMed ID: 8995493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin.
    Reyno LM; Egorin MJ; Eisenberger MA; Sinibaldi VJ; Zuhowski EG; Sridhara R
    J Clin Oncol; 1995 Sep; 13(9):2187-95. PubMed ID: 7666077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil.
    Anderson N; Lokich J; Moore C; Bern M; Coco F
    Cancer Invest; 1999; 17(8):586-93. PubMed ID: 10592766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor.
    Kornek GV; Haider K; Kwasny W; Hejna M; Raderer M; Meghdadi S; Burger D; Schneeweiss B; Depisch D; Scheithauer W
    Br J Cancer; 1996 Nov; 74(10):1668-73. PubMed ID: 8932353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy.
    Rosen PJ; Mendoza EF; Landaw EM; Mondino B; Graves MC; McBride JH; Turcillo P; deKernion J; Belldegrun A
    J Clin Oncol; 1996 May; 14(5):1626-36. PubMed ID: 8622081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
    Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
    Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study.
    Hussain M; Fisher EI; Petrylak DP; O'Connor J; Wood DP; Small EJ; Eisenberger MA; Crawford ED
    J Clin Oncol; 2000 Mar; 18(5):1043-9. PubMed ID: 10694555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer.
    Dawson NA; Figg WD; Cooper MR; Sartor O; Bergan RC; Senderowicz AM; Steinberg SM; Tompkins A; Weinberger B; Sausville EA; Reed E; Myers CE
    J Clin Oncol; 1997 Apr; 15(4):1470-7. PubMed ID: 9193342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
    Vogelzang NJ; Karrison T; Stadler WM; Garcia J; Cohn H; Kugler J; Troeger T; Giannone L; Arrieta R; Ratain MJ; Vokes EE
    Cancer; 2004 Jan; 100(1):65-71. PubMed ID: 14692025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cutaneous drug reaction caused by suramin in 4 patients with metastatic prostate cancer].
    Wichterich K; Tebbe B; Handke A; Dieckmann KP; Gollnick H
    Hautarzt; 1994 Feb; 45(2):84-7. PubMed ID: 8150636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.